KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Non-Current Assets (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Other Non-Current Assets for 6 consecutive years, with $53.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 60.46% year-over-year to $53.1 million, compared with a TTM value of $53.1 million through Sep 2025, down 60.46%, and an annual FY2024 reading of $27.3 million, down 71.03% over the prior year.
  • Other Non-Current Assets was $53.1 million for Q3 2025 at AbCellera Biologics, down from $57.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $134.2 million in Q3 2024 and bottomed at $9.5 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $54.9 million, with a median of $43.6 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets skyrocketed 354.43% in 2022, then plummeted 71.03% in 2024.
  • Year by year, Other Non-Current Assets stood at $30.6 million in 2021, then decreased by 8.3% to $28.1 million in 2022, then skyrocketed by 235.39% to $94.2 million in 2023, then tumbled by 71.03% to $27.3 million in 2024, then skyrocketed by 94.38% to $53.1 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ABCL at $53.1 million in Q3 2025, $57.5 million in Q2 2025, and $61.6 million in Q1 2025.